

# CCIS Strategic Planning

---

OMB No.: 0925-0642

Expiration Date: 3/31/2026

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

The Consortium for Cancer Implementation Science (CCIS) plays a pivotal role in addressing critical challenges and driving the implementation science (IS) in cancer agenda forward. The goal of this survey is to gather insight about the consortium, action groups, and public goods that aim to foster collaborations, identify solutions, and promote cross-disciplinary projects to transform the field.

**Please provide your feedback to this anonymous survey by September 15.** All questions are optional and you may exit the survey at any time.

---

How could the Consortium as a whole, beyond the activities within each action group, add value to the field of Cancer Implementation Science?

---

Page Break

Are there action group topic areas we should focus on in the future? Please list as many topics as appropriate. For each topic listed, please describe the activities you think the action group should engage in to accomplish the topic area you suggested. A new entry box will appear to capture each entry.

---

Page Break

Over the past four years, CCIS has used the Public Goods Model of developing tools and resources that further support and sustain the adoption of implementation science in cancer. Please provide any feedback on how this model has been in your experience.

Beyond supporting the development of individual public goods emerging from the action groups, what do you think the CCIS can do to incentivize growth in the field of implementation science in cancer?

Are there any further ideas or suggestions you have for ways that CCIS can add value?